30148-21-1Relevant articles and documents
CYCLIC AMINE DERIVATIVE AS AGENT FOR PROMOTING ADVILLIN FUNCTION, AND NOVEL CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
-
Paragraph 0116-0119, (2022/03/22)
An object of the present invention is to provide an agent for promoting advillin function that comprises a low molecular weight compound, and is useful for treatment of axonal injury. The present invention provides an agent for promoting advillin function, comprising a cyclic amine derivative typically represented by the following chemical formula, or a pharmacologically acceptable salt thereof as an active ingredient.
Photocatalytic acyl azolium-promoted alkoxycarbonylation of trifluoroborates
Scheidt, Karl A.,Zhu, Joshua L.
, (2021/06/28)
Despite recent advancements in the selective generation and coupling of organic radical species, the alkoxycarbonyl radical remains underexplored relative to other carbon-containing radical species. Drawing inspiration from new strategies for generating acyl radical equivalents utilizing dual N-heterocyclic carbene catalysis and photocatalysis, we have prepared dimethylimidazolium esters that can function as an alkoxycarbonyl radical surrogate under photocatalytic conditions. We demonstrate the synthetic utility of these azolium-based partners through the preparation of esters arising from the coupling of this radical surrogate with an oxidatively generated alkyl radical.
Application of 1-substituted-1H-imidazole-2-carboxylic acid compounds in preparation of metal beta-lactamase inhibitors
-
Paragraph 0070-0072, (2020/06/09)
The invention relates to application of 1-substituted-1H-imidazole-2-carboxylic acid compounds in preparation of metal beta-lactamase inhibitors, and particularly discloses application of compounds shown in a formula I in preparation of metal beta-lactamase inhibitors or antibacterial combined medicines. Experiments prove that the compounds provided by the invention can be used for effectively inhibiting the activity of various MBL enzymes including VIM-2, NDM-1, IMP-1, VIM-1 and VIM-5; the compounds, especially the compounds 11, 13, 14, 29, 30, 34, 37 and 40, have an IC50 value of 2.13 [mu] Mor less on the VIM-2 type MBL enzymes, have a more significant inhibition effect than positive control drugs, and have very good potential in the preparation of MBL enzyme inhibitors. Meanwhile, thecompounds disclosed by the invention are combined with beta-lactam antibiotics, so that metal beta-lactamase generated by drug-resistant bacteria can be effectively inhibited, the antibacterial activity of the antibiotics is enhanced, and the compounds have a very good application prospect in preparation of antibacterial combined medicines.